{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:10:16Z","timestamp":1756278616050,"version":"3.44.0"},"reference-count":23,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,4,16]]},"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:p>We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications.<\/jats:p>","DOI":"10.1136\/bcr-2018-229128","type":"journal-article","created":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T09:55:38Z","timestamp":1557136538000},"page":"e229128","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Successful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab"],"prefix":"10.1136","volume":"12","author":[{"given":"Chee Hoou","family":"Loh","sequence":"first","affiliation":[{"name":"Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Neurology, Royal North Shore Hospital, Saint Leonards, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey","family":"Herkes","sequence":"additional","affiliation":[{"name":"Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Neurology, Royal North Shore Hospital, Saint Leonards, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,5,5]]},"reference":[{"key":"2025082623332846000_12.5.e229128.1","unstructured":"World Health Organisation. Global Health Estimates. 2012 http:\/\/www.who.int\/healthinfo\/global_burden_disease\/en\/."},{"key":"2025082623332846000_12.5.e229128.2","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.118"},{"key":"2025082623332846000_12.5.e229128.3","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.117.019582"},{"key":"2025082623332846000_12.5.e229128.4","unstructured":"Royal College of Physicians United Kingdom. National Clinical Guideline for Stroke. Fifth edn, 2016:178."},{"key":"2025082623332846000_12.5.e229128.5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082623332846000_12.5.e229128.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707278"},{"key":"2025082623332846000_12.5.e229128.7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082623332846000_12.5.e229128.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2015.07.021"},{"key":"2025082623332846000_12.5.e229128.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.12.005"},{"key":"2025082623332846000_12.5.e229128.10","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00415-017-8410-6","article-title":"Adverse clinical outcomes after dabigatran reversal with idarucizumab to facilitate acute stroke thrombolysis","volume":"264","author":"Ng","year":"2017","journal-title":"J Neurol"},{"key":"2025082623332846000_12.5.e229128.11","doi-asserted-by":"crossref","unstructured":"Giannandrea D , Caponi C , Mengoni A , et al . Intravenous thrombolysis in stroke after dabigarran reversal with idarucizumab:case series and systemic review. J Neurol Neurosurg Psychiatry 2018:1\u20135.","DOI":"10.26226\/morressier.5ab8f55ad462b8029238d406"},{"key":"2025082623332846000_12.5.e229128.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.11.013"},{"key":"2025082623332846000_12.5.e229128.13","first-page":"e362","article-title":"ACCF\/AHA Guideline for the management of ST-Elevation myocardial infarction","volume":"2013","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"2025082623332846000_12.5.e229128.14","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ihj.2015.06.010","article-title":"Dabigatran for left ventricular thrombus","volume":"67","author":"Kolekar","year":"2015","journal-title":"Indian Heart J"},{"key":"2025082623332846000_12.5.e229128.15","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3389\/fphar.2018.00217","article-title":"Dabigatran added to dual antiplatelet therapy to treat a left ventricular thrombus in an 87 year old patient with myocardial infarction and very high bleeding risk","volume":"9","author":"Noflatscher","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025082623332846000_12.5.e229128.16","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.case.2018.04.008","article-title":"Large left ventricular thrombus as a cause of recurrent cardioembolic stroke while on Dabigatran","volume":"2","author":"Moey","year":"2018","journal-title":"CASE"},{"key":"2025082623332846000_12.5.e229128.17","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5853\/jos.2015.17.3.366","article-title":"Dabigatran effect on left ventricular thrombus in a patient with acute ischemic stroke","volume":"17","author":"Chung","year":"2015","journal-title":"J Stroke"},{"key":"2025082623332846000_12.5.e229128.18","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000024"},{"key":"2025082623332846000_12.5.e229128.19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.113.000253"},{"key":"2025082623332846000_12.5.e229128.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht148"},{"key":"2025082623332846000_12.5.e229128.21","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-012-0747-1"},{"key":"2025082623332846000_12.5.e229128.22","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3182491e14"},{"key":"2025082623332846000_12.5.e229128.23","doi-asserted-by":"publisher","DOI":"10.1177\/1747493018786616"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-229128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:33:40Z","timestamp":1756276420000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-229128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,5,5]]},"published-print":{"date-parts":[[2019,5]]}},"alternative-id":["10.1136\/bcr-2018-229128"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-229128","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}